interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Drospirenone

Generic competition · all medicines · read 12 November 2026

Is there a generic of Drospirenone, and who makes it?

Drospirenone appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Drospirenone2 dosage-form groups in the Orange Book
0generic makers listed
  1. Drospirenone appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Chewable, Oral

Nothing listed as marketed

Every brand product here is listed as discontinued. No generic is listed as marketed.

20202025203001brand 2022data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Slynd. No generic is listed as marketed.

2015202020252030203501brand 2019data datePatent 10179140 listed to expire 28 June 2031Patent 12090231 listed to expire 28 June 2031Patent 9603860 listed to expire 28 June 2031Patent 10603281 listed to expire 28 June 2031Patent 11413249 listed to expire 28 June 2031Patent 10849857 listed to expire 28 June 2031Patent 11951213 listed to expire 28 June 2031Patent 11478487 listed to expire 28 June 2031Patent 11504334 listed to expire 28 June 2031Patent 11123299 listed to expire 28 June 2031Patent 10987364 listed to expire 28 June 2031Patent 11291632 listed to expire 28 June 2031Patent 11291633 listed to expire 28 June 2031Patent 12280151 listed to expire 28 June 2031Patent 11351122 listed to expire 28 June 2031
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 28 June 2031Patent 10179140
  • 28 June 2031Patent 12090231
  • 28 June 2031Patent 9603860
  • 28 June 2031Patent 10603281
  • 28 June 2031Patent 11413249
  • 28 June 2031Patent 10849857 drug product
  • 28 June 2031Patent 11951213
  • 28 June 2031Patent 11478487 drug product

7 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.